+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

A

Actively Recruiting

Researchers are conducting a prospective, multicenter, observational registry study to better understand treatment approaches, clinical practice changes, and cardiorenal risk outcomes in Chinese patients with chronic kidney disease CKD. This study aims to collect real-world data from about 3000 participants across various hospital types and geographic regions in China, reflecting diverse clinical care settings. Participants diagnosed with CKD will be enrolled and followed for up to 96 weeks. Data will be gathered at multiple sites including top-tier tertiary hospitals, regional medical centers, and secondary hospitals. Information will be collected from medical records and entered into a cloud-based electronic system to ensure quality and accuracy. The study does not involve administering treatments but observes existing clinical practices. During the study, investigators will monitor clinical indicators and outcomes related to CKD and associated conditions such as hypertension, heart failure, and hyperkalemia over the 96-week period. Medication use and changes in treatment strategies will be tracked. Participants will provide informed consent before enrollment and their health data will be regularly reviewed to assess long-term outcomes and treatment patterns.

All AgesAll Genders
59 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of three perioperative treatment combinations for patients with HER2-expressing, locally advanced gastric or gastroesophageal junction adenocarcinoma. This phase II, open-label, randomized, multicenter trial compares Disitamab Vedotin plus Toripalimab and XELOX, Disitamab Vedotin plus Toripalimab, and XELOX alone to better understand their impact on this cancer type. The study involves three treatment groups one receiving the chemotherapy combination XELOX capecitabine and oxaliplatin, another receiving Disitamab Vedotin with Toripalimab, and a third group receiving all three treatments combined. Capecitabine is taken orally twice daily for 14 days every three weeks, oxaliplatin is given by intravenous infusion every three weeks, and Disitamab Vedotin and Toripalimab are administered intravenously every two weeks. Participants receive these treatments around the time of surgery. Participants will undergo assessments including pathological examinations to determine complete response rates, tumor regression, and surgical success, along with monitoring for adverse effects. The study will track outcomes such as remission rates, survival, and event-free survival for up to approximately two years. Evaluations include imaging and laboratory tests to monitor safety and treatment effects throughout the study period.

Age: 18Years +All GendersPhase 2
11 locations